Matrifen® for Therapy of Severe Chronic Pain®

NCT00699335 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 5308

Last updated 2012-05-08

Study results available
· View outcomes & findings →

Summary

The aim of the study was to evaluate the efficacy and safety of Matrifen® in patients with severe and chronic pain who could only be sufficiently treated with opioid analgetics (WHO class 3).

Conditions

  • Severe Chronic Pain

Interventions

DRUG

Fentanyl

Fentanyl transdermal patch. This was an observational study - therefore, the physician decided about dosage according to individual needs

Sponsors & Collaborators

  • Nycomed

    lead INDUSTRY

Principal Investigators

  • Dr. Thomas D. Bethke, MD, MBA · Nycomed Deutschland GmbH, 78467 Konstanz, Germany

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-06-30
Primary Completion
2009-07-31

Countries

  • Germany

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00699335 on ClinicalTrials.gov